Serum Amyloid Alpha in Parapneumonic Effusions
Study objectives. To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome. Methods. We studied prospectively 57 consecutive patients with PPE (empyema (EMP), complicated (CP...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2011/237638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559023910551552 |
|---|---|
| author | Vagelis Boultadakis Vasilis Skouras Demosthenes Makris Aggeliki Damianaki Dimitrios J. Nikoulis Theodoros Kiropoulos Smaragda Oikonomidi Irene Tsilioni Konstantinos Gourgoulianis |
| author_facet | Vagelis Boultadakis Vasilis Skouras Demosthenes Makris Aggeliki Damianaki Dimitrios J. Nikoulis Theodoros Kiropoulos Smaragda Oikonomidi Irene Tsilioni Konstantinos Gourgoulianis |
| author_sort | Vagelis Boultadakis |
| collection | DOAJ |
| description | Study objectives. To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome.
Methods. We studied prospectively 57 consecutive patients with PPE (empyema (EMP), complicated (CPE), and uncomplicated parapneumonic effusion (UPE)). SAA, CRP, TNF-α, IL-1β,
and IL-6 levels were evaluated in serum and pleural fluid at baseline. Patients were followed for 6-months to detect pleural thickening/loculations.
Results. Pleural SAA levels (mg/dL) median(IQR) were significantly higher in CPE compared to UPE (P<0.04); CRP levels were higher in EMP and CPE compared to UPE (P<0.01). There was no significant difference between IL-1β,
IL-6, TNF-α level in different PPE forms. No significant association between SAA levels and 6-month outcome was found. At 6-months, patients with no evidence of loculations/thickening had significantly
higher pleural fluid pH, glucose levels (P=0.03), lower LDH (P=0.005), IL-1β levels (P=0.001) compared to patients who presented pleural loculations/thickening.
Conclusions. SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis. SAA levels did not demonstrate considerable diagnostic
performance in identifying patients who develop pleural thickening/loculations after a PPE. |
| format | Article |
| id | doaj-art-b0231cadadd64357ae8dea9585382124 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-b0231cadadd64357ae8dea95853821242025-02-03T01:31:00ZengWileyMediators of Inflammation0962-93511466-18612011-01-01201110.1155/2011/237638237638Serum Amyloid Alpha in Parapneumonic EffusionsVagelis Boultadakis0Vasilis Skouras1Demosthenes Makris2Aggeliki Damianaki3Dimitrios J. Nikoulis4Theodoros Kiropoulos5Smaragda Oikonomidi6Irene Tsilioni7Konstantinos Gourgoulianis8Respiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, Greece“Sismanoglio” General Hospital of Attica, 15126 Athens, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceRespiratory Department, Chania General Hospital, 73300 Chania, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceRespiratory Department, University Hospital of Larissa, Biopolis, 41110 Larissa, GreeceStudy objectives. To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome. Methods. We studied prospectively 57 consecutive patients with PPE (empyema (EMP), complicated (CPE), and uncomplicated parapneumonic effusion (UPE)). SAA, CRP, TNF-α, IL-1β, and IL-6 levels were evaluated in serum and pleural fluid at baseline. Patients were followed for 6-months to detect pleural thickening/loculations. Results. Pleural SAA levels (mg/dL) median(IQR) were significantly higher in CPE compared to UPE (P<0.04); CRP levels were higher in EMP and CPE compared to UPE (P<0.01). There was no significant difference between IL-1β, IL-6, TNF-α level in different PPE forms. No significant association between SAA levels and 6-month outcome was found. At 6-months, patients with no evidence of loculations/thickening had significantly higher pleural fluid pH, glucose levels (P=0.03), lower LDH (P=0.005), IL-1β levels (P=0.001) compared to patients who presented pleural loculations/thickening. Conclusions. SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis. SAA levels did not demonstrate considerable diagnostic performance in identifying patients who develop pleural thickening/loculations after a PPE.http://dx.doi.org/10.1155/2011/237638 |
| spellingShingle | Vagelis Boultadakis Vasilis Skouras Demosthenes Makris Aggeliki Damianaki Dimitrios J. Nikoulis Theodoros Kiropoulos Smaragda Oikonomidi Irene Tsilioni Konstantinos Gourgoulianis Serum Amyloid Alpha in Parapneumonic Effusions Mediators of Inflammation |
| title | Serum Amyloid Alpha in Parapneumonic Effusions |
| title_full | Serum Amyloid Alpha in Parapneumonic Effusions |
| title_fullStr | Serum Amyloid Alpha in Parapneumonic Effusions |
| title_full_unstemmed | Serum Amyloid Alpha in Parapneumonic Effusions |
| title_short | Serum Amyloid Alpha in Parapneumonic Effusions |
| title_sort | serum amyloid alpha in parapneumonic effusions |
| url | http://dx.doi.org/10.1155/2011/237638 |
| work_keys_str_mv | AT vagelisboultadakis serumamyloidalphainparapneumoniceffusions AT vasilisskouras serumamyloidalphainparapneumoniceffusions AT demosthenesmakris serumamyloidalphainparapneumoniceffusions AT aggelikidamianaki serumamyloidalphainparapneumoniceffusions AT dimitriosjnikoulis serumamyloidalphainparapneumoniceffusions AT theodoroskiropoulos serumamyloidalphainparapneumoniceffusions AT smaragdaoikonomidi serumamyloidalphainparapneumoniceffusions AT irenetsilioni serumamyloidalphainparapneumoniceffusions AT konstantinosgourgoulianis serumamyloidalphainparapneumoniceffusions |